Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2011

Conditions
Multiple MyelomaNon-Hodgkin's LymphomaHodgkin's DiseaseMyelogenous LeukemiaLymphoblastic Leukemia
Interventions
DRUG

Tacrolimus

Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.

DRUG

Sirolimus

Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.

DRUG

G-CSF

Given starting on day 5 after transplant until the subjects white blood cell count recovers.

DRUG

Antithymocyte globulin

Given intravenously for 4 days before transplant (days 7, 5, 3, 1).

DRUG

Thymoglobulin

Given intravenously for 4 days before transplant (days 7, 5, 3, 1).

DRUG

Fludarabine

Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).

DRUG

Melphalan

Given intravenously on day 2 before transplant.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Massachusetts General Hospital

OTHER

NCT00133367 - Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | Biotech Hunter | Biotech Hunter